In Caucasian AEG/S patients, TROP2 is expressed in the majority of cases. TROP2 expression intensity itself has an impact on survival, which could be explained by a more aggressive phenotype, which leads to lymphatic invasion and lymph node metastasis.

6 days ago

Journal

TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

Trodelvy (sacituzumab govitecan-hziy)

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease (clinicaltrials.gov)

P1, N=32, Recruiting, Washington University School of Medicine | N=16 --> 32

6 days ago

Enrollment change

Signatera™

Hiltonol (poly-ICLC)

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)

P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026

7 days ago

Trial initiation date

docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (clinicaltrials.gov)

P1, N=15, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

8 days ago

Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

Keytruda (pembrolizumab) • Lenvima (lenvatinib)

Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma. (PubMed, Expert Rev Anticancer Ther)

Zolbetuximab exemplifies a novel therapeutic class which can be classified as targeted cytolytic antibodies. Future work should test combinations with checkpoint blockade, refine biomarkers and define resistance mechanisms.

8 days ago

Review • Journal • IO biomarker

CLDN18 (Claudin 18)

CLDN18.2 positive

Vyloy (zolbetuximab-clzb)

11d

ZANGEA: Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients (clinicaltrials.gov)

P2, N=80, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jan 2026

11 days ago

Enrollment open • Trial initiation date

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)

PD-L1 expression • HER-2 positive

Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)

11d

Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer (clinicaltrials.gov)

P1, N=30, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

11 days ago

Trial completion date • Trial primary completion date

carboplatin • paclitaxel

12d

Induction FLOT With CROSS CRT for Esophageal Cancer (clinicaltrials.gov)

P2, N=40, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Apr 2026 --> Jan 2026

12 days ago

Trial primary completion date

carboplatin • docetaxel • oxaliplatin

12d

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)

P2, N=126, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting

12 days ago

Enrollment closed

paclitaxel • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • bemarituzumab (AMG 552)